Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

Mr. Haviv's in-person presentation will highlight Evogene's new strategic focus on maximizing the value ofChemPass AI, the company's proprietary generative AI tech-engine, for the discovery and optimization of small molecules in both the pharmaceutical and agriculture industries. The presentation is scheduled forWednesday, September 10, 2025, at1:00 PM ET.

Mr. Haviv will also be available for one-on-one meetings. Interested investors and companies attending the conference are welcome to contact Evogene's Investor Relations team (details below) or, for H.C. Wainwright clients, schedule meetings directly through the conference's online platform.

Evogene Ltd.(NASDAQ:EVGN) (TASE: EVGN)is a pioneering AI-driven discovery and development company focused on creating novel small molecules for the pharmaceutical and ag-chemical industries. At the heart of Evogene's innovation isChemPass AI, a proprietary generative AI tech-engine purpose-built to design highly potent and unique small molecules optimized across multiple critical parameters.  By leveraging its tech-engine, Evogene address key challenges in small molecule discovery and optimization – significantly increasing the probability of success while reducing time and development costs. Evogene's powerful tech-engine drives product innovation through both strategic partnerships and collaborations, as well as through its internal proprietary product pipelines.

For more information, please visit:www.evogene.com.

Logo:https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg

SOURCE Evogene